NovoCure Toekomstige groei

Future criteriumcontroles 1/6

NovoCure is forecast to grow earnings and revenue by 4.1% and 9.4% per annum respectively. EPS is expected to grow by 5.1% per annum. Return on equity is forecast to be -63.2% in 3 years.

Belangrijke informatie

4.1%

Groei van de winst

5.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	18.6%
Inkomstengroei	9.4%
Toekomstig rendement op eigen vermogen	-63.2%
Dekking van analisten	Good
Laatst bijgewerkt	31 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BOVESPA:N2VC34 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	693	-157	-71	N/A	7
12/31/2025	627	-165	-59	-1	8
12/31/2024	597	-141	-78	-582	7
9/30/2024	578	-150	-78	-37	N/A
6/30/2024	550	-169	-104	-67	N/A
3/31/2024	526	-193	-121	-88	N/A
12/31/2023	509	-207	-100	-73	N/A
9/30/2023	504	-197	-89	-62	N/A
6/30/2023	508	-174	-46	-21	N/A
3/31/2023	522	-141	-5	18	N/A
12/31/2022	538	-93	9	31	N/A
9/30/2022	543	-82	20	49	N/A
6/30/2022	545	-68	24	51	N/A
3/31/2022	538	-59	36	61	N/A
12/31/2021	535	-58	59	83	N/A
9/30/2021	546	-27	106	122	N/A
6/30/2021	545	-5	113	128	N/A
3/31/2021	527	12	99	115	N/A
12/31/2020	494	20	84	99	N/A
9/30/2020	450	19	40	53	N/A
6/30/2020	409	12	24	37	N/A
3/31/2020	380	9	22	33	N/A
12/31/2019	351	-7	16	27	N/A
9/30/2019	322	-27	27	36	N/A
6/30/2019	294	-41	19	27	N/A
3/31/2019	269	-55	4	11	N/A
12/31/2018	248	-64	-9	-2	N/A
9/30/2018	232	-59	-28	-22	N/A
6/30/2018	217	-59	N/A	-25	N/A
3/31/2018	194	-64	N/A	-23	N/A
12/31/2017	177	-62	N/A	-33	N/A
9/30/2017	154	-73	N/A	-44	N/A
6/30/2017	125	-95	N/A	-80	N/A
3/31/2017	105	-114	N/A	-104	N/A
12/31/2016	83	-132	N/A	-108	N/A
9/30/2016	65	-143	N/A	-120	N/A
6/30/2016	52	-135	N/A	-109	N/A
3/31/2016	41	-124	N/A	-102	N/A
12/31/2015	33	-112	N/A	-100	N/A
9/30/2015	25	-102	N/A	-91	N/A
6/30/2015	20	-94	N/A	-87	N/A
3/31/2015	18	-86	N/A	-83	N/A
12/31/2014	15	-81	N/A	-74	N/A
12/31/2013	10	-77	N/A	-53	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: N2VC34 is forecast to remain unprofitable over the next 3 years.

Winst versus markt: N2VC34 is forecast to remain unprofitable over the next 3 years.

Hoge groeiwinsten: N2VC34 is forecast to remain unprofitable over the next 3 years.

Omzet versus markt: N2VC34's revenue (9.4% per year) is forecast to grow faster than the BR market (7.5% per year).

Hoge groei-inkomsten: N2VC34's revenue (9.4% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: N2VC34 is forecast to be unprofitable in 3 years.

NovoCure Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

NovoCure Limited Announces CFO Appointment

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

Novocure Announces Resignation of Todd Longsworth as General Counsel

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven